China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-10	US$2.550	+0.79%	22,134
26-07-09	US$2.530	-0.78%	11,819
26-07-08	US$2.550	+3.66%	87,992
26-07-07	US$2.460	+2.93%	36,539

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 16:00:00 2026-07-10 EDT			5-day change	1st Jan Change
2.550 ^USD	+0.79%		+4.08%	-98.94%

07-02	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI

Market Cap	82.16M 71.86M 66.28M 61.22M 116M 7.84B 118M 792M 311M 3.86B 308M 302M 13.27B	P/E 2025 *	-	P/E 2026	-0.18x
Enterprise Value	54.96M 48.07M 44.34M 40.95M 77.7M 5.24B 79.01M 530M 208M 2.58B 206M 202M 8.88B	EV / Sales 2025	9.81x	EV / Sales 2026	-22.6x
Free-Float	99%	Yield 2025 *	-	Yield 2026	-

07-02	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
12-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
25-07-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-03-28	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
25-03-17	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT
25-01-23	China SXT Pharmaceuticals, Inc. Announces CEO Changes	CI
25-01-23	China SXT Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
25-01-20	China SXT Pharmaceuticals, Inc. announced that it expects to receive $2.84 million in funding	CI
24-08-13	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI
24-08-12	China SXT Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-05-12	China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	CI

07-01	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
01-30	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
01-15	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN	AQ
01-13	Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)	AQ

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1650

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.79%
1 week	+4.08%
Current month	+20.85%
1 month	-0.78%
3 months	+9.91%
6 months	-88.05%
Current year	-98.94%

1 week	2.31	2.82
1 month	1.89	2.93
Current year	1.25	1,046.98
1 year	1.25	1,046.98
3 years	1.25	11,249.94
5 years	1.25	1,000,000
10 years	1.25	1,000,000

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	2025-01-19
Feng Zhou CEO	Chief Executive Officer	34	2017-07-03
Xiaodong Pan DFI	Director of Finance/CFO	49	2022-01-30

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	2017-07-03
Jun Zheng BRD	Director/Board Member	49	2018-12-30
Xiaodong Ji BRD	Director/Board Member	57	2021-05-21

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	+0.79%	+4.08%	-99.03%	-99.96%	82.16M
ELI LILLY AND COMPANY	-0.86%	-2.09%	+49.88%	+169.76%	1,060B
JOHNSON & JOHNSON	+0.26%	-2.30%	+63.79%	+62.56%	619B
ABBVIE INC.	-0.44%	-4.98%	+28.91%	+83.79%	438B
ROCHE HOLDING AG	-0.80%	+0.54%	+29.45%	+24.66%	333B
NOVARTIS AG	-0.05%	-1.17%	+28.22%	+46.15%	282B
ASTRAZENECA PLC	-1.31%	-10.75%	+18.03%	+21.82%	267B
NOVO NORDISK A/S	-0.05%	+0.09%	-27.49%	-38.54%	218B
AMGEN INC.	-0.72%	-2.88%	+23.07%	+61.02%	196B
GILEAD SCIENCES, INC.	-0.47%	-1.10%	+18.41%	+69.98%	161B
Average	-0.31%	-2.59%	+13.32%	+40.13%	357.4B
Weighted average by Cap.	-0.46%	-3.10%	+36.11%	+83.17%

	2025	2026
Net sales	1.74M 1.52M 1.4M 1.3M 2.46M 166M 2.5M 16.78M 6.59M 81.8M 6.54M 6.39M 281M	1.14M 995K 918K 848K 1.61M 109M 1.64M 10.97M 4.31M 53.47M 4.27M 4.18M 184M
Net income	-3.3M -2.89M -2.67M -2.46M -4.67M -315M -4.75M -31.85M -12.51M -155M -12.4M -12.13M -534M	-6.21M -5.43M -5.01M -4.62M -8.77M -592M -8.92M -59.82M -23.49M -292M -23.3M -22.79M -1B
Net Debt	-17.25M -15.09M -13.92M -12.86M -24.39M -1.65B -24.8M -166M -65.31M -811M -64.78M -63.37M -2.79B	-27.2M -23.79M -21.94M -20.27M -38.46M -2.59B -39.11M -262M -103M -1.28B -102M -99.91M -4.39B